CN116003564A - 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新 - Google Patents

作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新 Download PDF

Info

Publication number
CN116003564A
CN116003564A CN202210859133.9A CN202210859133A CN116003564A CN 116003564 A CN116003564 A CN 116003564A CN 202210859133 A CN202210859133 A CN 202210859133A CN 116003564 A CN116003564 A CN 116003564A
Authority
CN
China
Prior art keywords
yap
yap5sa
seq
cells
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210859133.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·蒙洛
J·里奇
J·F·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of CN116003564A publication Critical patent/CN116003564A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
CN202210859133.9A 2017-03-14 2018-03-14 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新 Pending CN116003564A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471204P 2017-03-14 2017-03-14
US62/471,204 2017-03-14
PCT/US2018/022496 WO2018170172A1 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
CN201880025311.XA CN110520112A (zh) 2017-03-14 2018-03-14 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880025311.XA Division CN110520112A (zh) 2017-03-14 2018-03-14 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新

Publications (1)

Publication Number Publication Date
CN116003564A true CN116003564A (zh) 2023-04-25

Family

ID=63523973

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880025311.XA Pending CN110520112A (zh) 2017-03-14 2018-03-14 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新
CN202210859133.9A Pending CN116003564A (zh) 2017-03-14 2018-03-14 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880025311.XA Pending CN110520112A (zh) 2017-03-14 2018-03-14 作为Hippo效应子的显性活性Yap诱导染色质可及性和心肌细胞更新

Country Status (10)

Country Link
US (3) US11484553B2 (enExample)
EP (1) EP3595642A4 (enExample)
JP (3) JP2020513810A (enExample)
CN (2) CN110520112A (enExample)
AU (2) AU2018234632B2 (enExample)
BR (1) BR112019018912A2 (enExample)
CA (1) CA3056231A1 (enExample)
IL (2) IL269187B2 (enExample)
MX (2) MX2019010986A (enExample)
WO (1) WO2018170172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018223062A1 (en) * 2017-06-01 2018-12-06 Baylor College Of Medicine Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
WO2021119030A1 (en) * 2019-12-09 2021-06-17 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20210324412A1 (en) * 2020-04-15 2021-10-21 University Of Southern California Activation of yap signaling for sensory receptor regeneration
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
US20230193267A1 (en) * 2021-10-19 2023-06-22 Animatus Biosciences, Inc. Cardiac cell proliferation by administering inhibitors of sav1, nf2, mob1 and/or mutant srf
WO2024168269A1 (en) * 2023-02-10 2024-08-15 Baylor College Of Medicine Use of mutant yap for improving cardiac function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途
US20160287724A1 (en) * 2013-11-18 2016-10-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2110899C (en) 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
TW563139B (en) 2000-11-30 2003-11-21 Nec Tokin Corp Magnetic core including magnet for magnetic bias and inductor component using the same
US8140593B2 (en) * 2008-05-15 2012-03-20 Microsoft Corporation Data viewer management
KR101057116B1 (ko) 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2015121323A1 (en) * 2014-02-11 2015-08-20 Institut Pasteur Treatment of cardiac diseases with modulators of the hippo pathway
WO2016044096A1 (en) * 2014-09-16 2016-03-24 Albert Einstein College Of Medicine Of Yeshiva University Repopulation of organs and tissues using a yap-ert2 fusion protein
GB201819659D0 (en) * 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287724A1 (en) * 2013-11-18 2016-10-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALEXANDER VON GISE等: "YAP1，the nuclear target of Hippo signaling，stimulates heart growth through cardiomyocyte proliferation but not hypertrophy", PNAS, vol. 109, no. 7, 30 January 2012 (2012-01-30), pages 2396 *
BIN ZHAO等: "A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP", GENES & DEVELOPMENT, vol. 24, no. 1, 31 December 2010 (2010-12-31), pages 73, XP055748250, DOI: 10.1101/gad.1843810 *
ZHIQIANG LIN等: "Cardiac-Specific Y AP Activation Improves Cardiac Function and Survival in an Experimental Murine MI Model", CIRCULATION RESEARCH, vol. 115, no. 3, 15 May 2014 (2014-05-15), pages 354, XP055183368, DOI: 10.1161/CIRCRESAHA.115.303632 *
李达等: "绵羊YAP1基因的克隆及其真核表达载体和突变型载体的构建", 畜牧兽医学报, no. 8, 31 December 2013 (2013-12-31), pages 1198 - 1204 *

Also Published As

Publication number Publication date
CA3056231A1 (en) 2018-09-20
US12138284B2 (en) 2024-11-12
JP2020513810A (ja) 2020-05-21
US11484553B2 (en) 2022-11-01
JP2024073571A (ja) 2024-05-29
EP3595642A1 (en) 2020-01-22
IL269187B2 (en) 2024-04-01
IL308112A (en) 2023-12-01
AU2018234632B2 (en) 2024-06-13
WO2018170172A1 (en) 2018-09-20
AU2024219497B2 (en) 2025-08-14
US20230063735A1 (en) 2023-03-02
CN110520112A (zh) 2019-11-29
JP2022164658A (ja) 2022-10-27
MX2022011881A (es) 2022-11-09
IL308112B1 (en) 2024-09-01
AU2018234632A1 (en) 2019-10-03
IL269187B1 (en) 2023-12-01
JP7461071B2 (ja) 2024-04-03
BR112019018912A2 (pt) 2020-04-14
US20200016212A1 (en) 2020-01-16
AU2024219497A1 (en) 2024-10-03
IL269187A (en) 2019-11-28
MX2019010986A (es) 2020-02-05
US20250073276A1 (en) 2025-03-06
IL308112B2 (en) 2025-01-01
EP3595642A4 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
JP7461071B2 (ja) クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
US20230036788A1 (en) Compositions and methods of using tyrosine kinase inhibitors
CN111479570A (zh) 用于治疗与dux4表达相关的疾病的化合物
US20210077582A1 (en) Compositions and methods for increasing the efficacy of anti-pd-1 antibody immunotherapy
Choi et al. Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival
CN114592062A (zh) 氯喹在增效替莫唑胺治疗ptrf高表达的胶质母细胞瘤中的应用
US20240197760A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
KR101921676B1 (ko) Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법
Nayakanti Role of FoxO3 transcription factor in right ventricular remodeling and failure
CN118697878B (zh) Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用
Cruz Cruz The Role of MDM2 in Mouse Development and its Implication in the Pathogenesis of Cancer and Developmental Diseases
Cruz The Role of MDM2 in Mouse Development and its Implication in the Pathogenesis of Cancer and Developmental Diseases
US20210115521A1 (en) Method for inhibiting tumor progression or determining tumor progression state in gastric cancer
HK40057503A (en) Compositions and methods of using tyrosine kinase inhibitors
Vanoni et al. Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas A C
DE STEFANO PIN1 as new oncogene in ovarian cancer: function and chemical inhibition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination